The privately-held biotechnology company has developed a proprietary platform isolation technology that is cell-free and has the potential to demonstrate a safer, lower-cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegle's EV therapy has the potential for functional regeneration and organization of complex tissue structures that can enhance healing, reduce scarring, minimize contraction, and improve overall cosmesis. The company's IND for DEB has been cleared by the FDA, and it expects to enter the clinic by the 2H of 2020.